Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06642571 · ClinicalTrials.gov registry record · Phase 1
A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT06642571 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 46 participants.
The verdict
NCT06642571, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study will look into a new study medicine called NNC0519-0130 to improve the treatment option for people living with excess body weight or type 2 diabetes or both. The purpose of this study is to compare the amount of NNC0519-0130 in the blood of participants who have excess body weight. The study comprises two parts and the participants will receive both preparations NNC0519-0130 B and NNC0519-0130 C, which treatment the participants get is decided by chance. The study will last for about 24 weeks.
Interventions
- DRUG NNC0519-0130 B
- DRUG NNC0519-0130 C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2024-10-15 |
| Est. Completion | 2025-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06642571
The ClinicalTrials.gov registry entry for NCT06642571 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NNC0519-0130 B is the first listed.
NCT06642571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06642571 about?
NCT06642571 is a clinical study titled "A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine". This study will look into a new study medicine called NNC0519-0130 to improve the treatment option for people living with excess body weight or type 2 diabetes or both. The purpose of this study is to compare the amount of NNC0519-0130 in the blood of participants who have excess body weight. The st...
What is the current status of trial NCT06642571?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2024-10-15. Estimated completion is 2025-05-31.
What interventions are being tested in trial NCT06642571?
The interventions under investigation include: NNC0519-0130 B (DRUG), NNC0519-0130 C (DRUG).
Who is sponsoring clinical trial NCT06642571?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.